Geneva, January 1 st , 2021 Terapet SA, a privately held Swiss MedTech company developing innovative solutions for a safer, more precise, and time-saving proton therapy for cancer treatment, announced today the combined successful awards of a total of about CHF 1’530’000 non-dilutive funds. The combined funding supports the development of Terapet’s first full-scale prototype to be installed for clinical validation and for building two strong consortia between Terapet and world class research institutes: one with CERN, funded through the Innosuisse Innovation Project, and one with Karolinska Institute and the first Nordic Proton Therapy facility, Skandion Clinic, funded through the Eurostars Program.
Both research and development collaborations will officially start on 01.02.2021 and last for the coming 3 years. All the research parties in the consortium are fully funded.
About Eurostars (E!114620 ACCELERATE)
Terapet together with their clinical partners, ranked 2 out of 500 eligible projects across Europe by European Commission, receives a total of € 700,000 non-dilutive grant financed by Innosuisse, the Swiss Innovation Agency and Vinnova, the Swedish Innovation Agency. News on Venturelab.
About Innosuisse (45198.1 IP-LS)
Innosuisse has been supporting Terapet SA since the very start of the project: Start-up training courses, Initial Coach Program, Core Coach Program, Mentoring as well as the Innosuisse Innovation Cheque for the initial collaboration with CERN.
Terapet thanks Innosuisse being a crucial partner who has truly supported Terapet to transform the idea to a real company.
Read the press release: Terapet SA Press Release collaborations
News on Startupticker.ch
News on CERN-KT